Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue        
Product revenue, net $ 19,610 $ 9,447 $ 45,617 $ 30,808
Collaboration revenue 1,446 0 4,646 0
Revenue - related party 29 28 252 1,042
Net revenue 21,085 9,475 50,515 31,850
Operating expenses        
Cost of goods sold - product revenue 11,167 3,379 22,559 10,313
Research and development 27,367 13,298 70,226 43,868
Research and development - licenses acquired 713 458 15,585 2,278
Selling, general and administrative 22,221 15,383 59,145 45,358
Wire transfer fraud loss 9,540 0 9,540 0
Total operating expenses 71,008 32,518 177,055 101,817
Loss from operations (49,923) (23,043) (126,540) (69,967)
Other income (expense)        
Interest income 132 265 505 1,228
Interest expense and financing fee (4,444) (6,958) (9,393) (13,142)
Change in fair value of investments 8,376 575 39,294 575
Change in fair value of derivative liability (2) (803) (184) (1,189)
Total other income (expense) 4,062 (6,921) 30,222 (12,528)
Net loss (45,861) (29,964) (96,318) (82,495)
Net loss attributable to non-controlling interests 25,080 14,417 63,180 41,264
Net loss attributable to common stockholders $ (20,781) $ (15,547) $ (33,138) $ (41,231)
Net loss per common share - basic and diluted $ (0.56) $ (0.39) $ (1.19) $ (1.19)
Net loss per common share attributable to non - controlling interests - basic and diluted (0.31) (0.19) (0.78) (0.59)
Net loss per common share attributable to common stockholders - basic and diluted $ (0.26) $ (0.20) $ (0.41) $ (0.59)
Weighted average common shares outstanding - basic and diluted 81,348,243 76,093,211 81,056,165 69,404,499